Quarterly Activities & Cashflow Report | Optiscan

Highlights for the Quarter

  • Met with the United States Food and Drug Administration seeking feedback for a 510(k) submission in Oral Cancer Surgery and/or Oral Cancer Screening.
  • Progress in Oral Cancer Trials and Studies being led by Memorial Sloan Kettering Cancer Centre, Melbourne Dental School and Australian Centre for Oral Oncology Research and Education.
  • Leading medical journal, Nature Biomedical Engineering, published study confirming potential of OptiScan technology.
  • Revenue from Carl Zeiss Meditec of approximately $500k.
  • Delivery of a FIVE2 (ViewnVivo) system to a university in Shanghai –OptiScan’s first China sale with
    new distribution arrangements.
  • Receipt of $211k from financing of Research and Development Tax Credit.

To read the full  quarterly report click here.

About Optiscan

OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets.   Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery.  Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy.  The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.

Register Interest